At the news
? NEUTRALIMPACT 2/10 144 filed Nov 13, 2026 at 16:05 ET
Director Douglas Kerr filed a Form 144 notice of intent to sell 2,604 shares of Dyne Therapeutics common stock, with an estimated aggregate market value of approximately $43,810. The shares were acquired through restricted stock unit vesting and equity compensation. The sale is small relative to the company's $3.4B market cap and represents a routine insider transaction.
- Director Douglas Kerr filed Form 144 on 2026-11-13 to sell 2,604 shares of common stock.
- Estimated aggregate market value of the proposed sale is $43,810.
- Shares were acquired via restricted stock unit vesting and equity compensation.
- The filing indicates a prior sale of 3,745 shares on 2026-09-04 and 1,290 shares on 2026-09-08.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access